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Bifurcation coronary lesions are commonplace, but present a diffi-
cult challenge to the interventional cardiologist, with a high compli-
cation rate in both the long and short term1. Major adverse cardiac
events (MACE) are significantly higher in bifurcation versus non-
bifurcation lesions2 and this is chiefly attributable to target vessel
revascularisation rather than death or myocardial infarction3.
The first meeting of the European Bifurcation Club took place on
15th to 16th of September, 2005 in Bordeaux and was organised by
Drs. Thierry Lefèvre, Yves Louvard, Remo Albiero, Olivier
Darremont, Manuel Pan and Goran Stankovic. The aim was to bring
together an invited faculty of European cardiologists involved in this
field to discuss optimal strategies for treating bifurcation coronary
artery disease and also to interact with the industry. After 36 hours
of discussions an attempt was made to reach a consensus view,
and this manuscript reflects the results of these discussions.
The following topics were considered:
– Definitions
– Pharmacology






– Dedicated bifurcation devices
Definitions
Definition and classification of bifurcation coronary disease is not
straightforward. A general consensus exists that if a branch vessel
is large enough to be stented, then the coronary division merits the
term “bifurcation”. This does not take account of any difference in
relative size of the two vessels in question, but does have the advan-
tage of uniformity. In practice, therefore, divisions where branch
vessels of > 2.25 mm diameter emerge are considered to represent
bifurcations. The pattern of disease at the bifurcation may be fur-
ther classified into “true” bifurcations (where the lesion involves
both the main and side vessels to a significant degree – ICPS
types 1 and 4) and “false” bifurcations (where only the main or side
vessel is significantly involved – ICPS types 2, 3, 4a, 4b) at a bifur-
cation. The relative value of distinguishing between true and false
bifurcations has not been established.
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There are several eponymous classification systems in use, but
none has gained full acceptance. The most widely used is the ICPS
classification4. This however is not a particularly “intuitive” classifi-
cation and can be difficult to remember in clinical practice. The
MEDINA classification5 was considered to be the most simple to
understand and use and was adopted by everybody (Figure 1).
It is not likely that any randomised trials will be performed with a pri-
mary end-point of SAT. It could be that large “real world” registries
(such as the Medtronic “E5” using the Endeavor™ stent and the
Boston Scientific “Olympia” registry using the Taxus Liberte™ stent)
could at least provide the incidence of SAT with the use of DES in
bifurcation disease.
Imaging and QCA of bifurcation lesion
Imaging of bifurcation coronary disease remains problematic.
Multiple 2D imaging planes may be required before a clear image
of the bifurcation is achieved, and in some cases, optimal imaging
of the bifurcation is never truly achieved due to poor ostiale visuali-
sation of the side branch and/or foreshortening of the vessel.
Recently, Ludwig et al have been experimenting with novel 3D
reconstruction software, to offer superior anatomical assessment of
the bifurcation lesion, and also to calculate the optimal caudal/cra-
nial and left/right angulation required to best visualise the bifurca-
tion. This technology (Paieon Medical Ltd, Israel) was enthusiasti-
cally received at the meeting. Intravascular ultrasound has taught
us the importance of kissing balloon inflations following complex
bifurcation stenting11, but is not itself considered necessary for the
correct undertaking of bifurcation angioplasty. The importance of
understanding the Murray’s law12 was clearly pointed out by Gérard
Finet from Lyon, France who confirmed in vivo the mathematical
relationship between the diameter of both branches (MB and SB)
of the bifurcation and the Proximal Branch (PB): PB (mm) =
(MB+SB) x 0.67 (in a constant flow model this ratio is 0.71).This
formula can be very useful for evaluating the correct proximal refer-
ence diameter in a bifurcation lesion, especially for distal left main.
It can be used also to determine the reference diameter of the side
branch when diseased (knowing the proximal and distal main
branch reference diameter). This rule is now used in a new experi-
mental QCA software which was presented by General Electric.
Medis has also developed a new software dedicated to analysis of
bifurcation lesions.
Plaque modification
One of the major problems during percutaneous treatment of bifur-
cations is plaque shift. There is therefore a theoretical advantage to
including plaque modification in the strategy. There are proponents
of various techniques, including use of the cutting balloon13, rotab-
lation14 and atherectomy15. None, however, has clearly been shown
to be beneficial in any randomised trial of technique, and there
remains no consensus about the value of these ancillary tech-
niques.
Technique
There are many described techniques for the treatment of bifurca-
tion lesions. These include; main-vessel-only stenting, provisional
side branch T-stenting; T-stenting, modified T-stenting, culotte,
crush, V-stenting, shotgun and simultaneous kissing stents16. Many
of these techniques are minor variations on a theme and provision-
al techniques may still end up with complex stenting17. An attempt
to classify these treatments into types A-D has been made16.
Randomised trials are difficult to do: each patient’s anatomy may
Figure 1.
Bifurcation site
Not all bifurcations are the same, and this is particularly the case for
distal Left Main Stem disease – the “big bifurcation”. Whereas
branch vessels can be considered of subsidiary importance, the left
main stem subtends the circumflex and left anterior descending
coronary arteries, neither of which can be ignored or sacrificed with
impunity (with the exception of vestigial non-dominant circumflex
vessels) Therefore the left main stem has “special status” within
bifurcations. Important data on the treatment of left main stem dis-
ease, including the interventional treatment of distal bifurcation dis-
ease will be available from the SYNTAX trial which is well into the
recruitment phase.
Pharmacology
Preloading with clopidogrel and aspirin is routine for coronary inter-
ventions and this applies equally to bifurcation disease. Additional
elective use of glycoprotein IIb/IIIa inhibitors is currently considered
the optimal pharmacological approach, but use of these drugs is
decreasing, and further data from the ISAR REACT study series6
could potentially influence activity further.
One of the main concerns with bifurcation stenting, particularly if
a double stent technique is used (either deliberately or as the final
phase of a provisional T-stent strategy) is of SubAcute stent
Thrombosis (SAT). Using drug-eluting stents, SAT may be more
common with complex stenting techniques, as it was in the BMS
era7. There is a suggestion from the “Research” and “T-search”
Registries8,9 that routine use of Gp2b3a inhibitors with complex
bifurcation stenting may reduce the rate of SAT. However there is no
data showing that late stent thrombosis after complex stenting is
reduced by the adjunctive use of antiplatelet treatment10.
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favour a particular technique, but trial patients overall will be hetero-
geneous. During the first European Bifurcation Club meeting the fol-
lowing comments were made by experts in the field:
“It may be impossible to do randomised trials: every patient needs
an individual treatment.”
“Every technique is potentially provisional when using type B treat-
ment (first stenting the main branch), we can do a provisional
culotte, provisional T, provisional crush...”
In the era of bare metal stents, consensus would appear to favour
the “simple” (attempted single stent) approach, compared to the
complex (planned double stent) approach. No randomised data is
available, but several registries appear to favour the “provisional” T
stenting approach2-15. Difficulties with these registries include:
– They are often not assessed with an intention to treat manner.
– Side branch stents are often placed as a result of poor results or
complications. Therefore a systematic bias favours the single
stent patients, as they have “easier” lesions with better initial out-
comes.
– The techniques used for double stenting vary from registry to reg-
istry. Even the names of the techniques, as well.
– The classification of the bifurcation types and treatment is not
always clear.
Despite these shortcomings, the recurring theme of these registries
is that for bare metal stents, deliberate double stent techniques are
not superior, and may be inferior, to attempted single stent tech-
niques involving provisional treatment of the side branch. In the era
of drug-eluting stents however, given the very low rates of resteno-
sis of these stents, it will be important to re-examine this issue.
Data so far for the more complex techniques employing drug-elut-
ing stents are limited. The Colombo trial utilising sirolimus-eluting
stents is difficult to interpret, as there was a very high crossover rate
from single to dual vessel stenting. Per-protocol angiographic
restenosis (>50% in either vessel) was seen in 28% of the stent-
stent versus 18% of the provisional stent group18. In the ran-
domised study of Pan et al19, a very low rate of cross-over was
observed but the trend was the same: a higher rate of restenosis,
TVR and MACE in the 2 stents group.
If a complex strategy is employed, kissing balloon angioplasty is an
important final part of the procedure20,21 both to reduce restenosis
at the ostium of the side branch, and possibly to facilitate future
access to the side branch. However, recrossing a stent crush is not
always possible.
If a simple technique is employed, immediate patency of the side
branch is more easily achieved with a wire jail than without22.
Certainly, the 2nd wire favourably modifies the angle between the
2 vessels23, and is a good marker of the side branch should it
occlude during stenting of the parent vessel. There are no data,
however, to establish clearly whether a kissing inflation is necessary
with the provisional T-stent strategy if there is good flow in the side
branch after initial deployment of the stent in the main vessel.
How can this field be moved forward from
“anecdotalism” to clinical science?
There are a number of options for clinical trials which will allow the
delineation of the optimal treatment of bifurcation coronary disease:
Philosophical
There are two potential areas where a philosophical approach in
bifurcation disease could be tested. The first would be a trial of per-
cutaneous intervention versus coronary artery bypass grafting.
However, as percutaneous intervention has advanced, so it has
become more difficult to randomise patients into this type of trial,
and although there are several ongoing trials randomising patients
to either an interventional or a surgical management of their coro-
nary disease, it is doubtful that a randomised trial of surgical versus
interventional management of LAD/diagonal bifurcation coronary
disease could successfully take place.
The second potential for a “philosophical” trial would be one com-
paring “flow” versus “anatomy”. The most simple approach to a
bifurcation lesion is to stent the main vessel and only intervene on
the side branch if the flow in the side-branch is compromised. This
could be compared to a strategy requiring angiographic anatomi-
cal optimisation, such that no stenosis of >50% could be left
untreated “per protocol”. Two such studies are currently being per-
formed, each at differing levels of completion. The Nordic
Bifurcation Study has enrolled 400 patients with bifurcation dis-
ease. Randomisation is between a simple (provisional side branch
T-stenting) and a complex strategy (crush, culotte or T stenting
with final kissing balloon inflation) using the Cypher stent. The pri-
mary endpoint is a composite of death, myocardial infarction, and
target vessel revascularisation, at 6 months, with an additional
angiogram at 8 months. This nice design allows clinical endpoints
to take priority, while also providing subsequent angiographic data.
The BBC ONE study is being performed in the UK. This will com-
pare simple (provisional T with final kissing) and complex strate-
gies (crush or culotte with final kissing) in 500 patients using the
Taxus stent. The primary end-point in this study is a composite of
death, myocardial infarction and target vessel failure at 9 months.
Between them therefore, these 2 studies will include nearly 1,000
patients randomised to simple or complex strategies, and are suf-
ficiently similar to allow possible meta-analysis. Hopefully, this will
give a clear answer as to the correct baseline strategy for bifurca-
tion coronary disease, and indeed may hint as to whether one
drug-eluting stent has an advantage over another.
Physiological
The alternative approach would be to assess the physiological sig-
nificance of any residual or “new” lesion in the side branch, follow-
ing plaque shift, using pressure wire derived Fractional Flow
Reserve (FFR). This might present technical difficulties manipulat-
ing the pressure wire through the parent vessel stent. Also, imme-
diate pressure-wire derived assessment may not be representative
of the physiology of the side branch ostium over time – pressure
wire data were initially derived from chronic stable anatomy, and the
anatomy of a recently stented bifurcation does not conform to this.
Some data, however, has been presented with this technique, “jail-
ing” the pressure wire during the procedure, and suggests that
angiography alone is unreliable in assessing the functional severity
of jailed side branches – many side branches with a >75% angio-
graphic stenosis had an FFR >0.75 suggesting that no further inter-
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vention was required24. To try to answer this question a prospective
randomised study will be designed.
New devices
Dedicated bifurcation devices have had only moderate success so
far25 in bare metal format, but may yet prove useful, particularly for
the left main stem when the DES format is available. One device
currently being assessed is the Devax stent (Axxess Plus study),
a unique self expanding stent which is deployed in the parent ves-
sel (carena device), followed by distal stenting in the main and/or
the side branch as required. Preliminary data with this device are
very promising and a First-in-Man study with a Devax left main DES
carena device is now ongoing.
A number of dedicated stent designs in DES format are in develop-
ment (dedicated provisional T approach devices: Twin-Rail,
Frontier, Petal, sidekick, Nile; Side branch stents: Capella, Tryton;
and carena devices: Axxess plus). When mature, they may offer an
advance in bifurcation treatment options, particularly with respect to
the left main stem. Randomised trials of these devices appear
unlikely and we may well have to rely on registry data to decide on
the relative merit of each new device.
Conclusions
Randomised trials in bifurcation coronary disease are difficult
because of the heterogeneous nature of the anatomy of bifurca-
tions. A consensus view of the definition of bifurcation anatomy
would be very useful and the MEDINA classification would appear
to provide this. Registry data may be required to assess complica-
tion rates such as subacute or late stent thrombosis. Randomised
trials of a “simple” versus a “complex” approach are, however, pos-
sible and two such trials are currently under way. In the absence of
randomised data to the contrary, a “simple” approach to bifurcation
lesions would seem to be reasonable. If one technique is shown to
be superior to the other, then subsequent new devices could be
assessed in a registry format against this gold standard. The left
main stem presents a particular challenge to the interventional car-
diologist. The SYNTAX trial should offer a baseline for intervention-
al therapies in this area – this cohort could then, again, be tested
against new devices using the SYNTAX group or the Bifurcation
group of patients included in ARTS II26 as historical controls.
Much work remains to be done in percutaneous treatment of coro-
nary bifurcation lesions. However, gradually some consensus
appears to be emerging in this difficult field and we are hopeful that
a standard approach will emerge over the next 3-5 years.
Consensus was reached on the following issues
– The MEDINA classification should be more widely adopted (see
Figure 1)
– With bare metal stents, a stepwise provisional T-stent strategy is
the gold standard
– With bare metal stents, deliberate double-stenting may be an
inferior technique
– With drug-eluting stents, the optimal strategy is under development,
and two ongoing trials (Nordic and BBC1) will help define this.
– After complex stenting, kissing balloon inflations should be rou-
tinely performed.
There is still debate
– A precise, simple and easy to retain definition of treatments is still
necessary.
– In bifurcation lesions with no significant side branch involvement
should we end always with a kissing or jail the side branch?
– Is the answer different for distal left main?
In true bifurcation lesions with relatively long side branch lesion (> 3
to 5 mm in length), there is a consensus for the use of 2 stents but
what is the best treatment with 2 stents: T stenting, minicrush,
crush, culotte?
Maybe the answer will come, not only from randomised studies, but
also from bench testing?
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